Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation

ConclusionsRebound syndrome is an intractable complication of exit strategy for fingolimod ‐treated RRMS patients. To lower the risk for rebound syndrome, specific mechanisms of rebound syndrome are to be clarified. Furthermore, concise risk stratification for progressive multifocal leukoencephalopathy in fingolimod treatment is imperative. Taken together, the risk–benefit analysis fo r fingolimod treatment, including rebound syndrome as well as progressive multifocal leukoencephalopathy, is required to initiate the drug.

Source: Clinical and Experimental Neuroimmunology - March 13, 2019 Category: Neurology Authors: Hiroshi Kuroda, Shuhei Nishiyama, Yuki Matsumoto, Tatsuro Misu, Kazuo Fujihara, Masashi Aoki Tags: Case Report Source Type: research